HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TUCSON, Ariz., Aug.  04, 2020  (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the pre-launch introduction of its new HTG EdgeSeq Reveal RUO oncology applications, which are expected to be commercially available globally in late August with the release of HTG EdgeSeq Reveal version 3.0.

HTG Introduces HTG EdgeSeq Reveal RUO Oncology Applications

Entire HTG RUO profiling assay menu now available for use on both Illumina’s and Thermo Fisher Scientific’s NGS platform Entire HTG RUO profiling assay menu now available for use on both Illumina’s and Thermo Fisher Scientific’s NGS platform

HTG Expands RUO Profiling Menu with New NGS Platform Capability Assays

TUCSON, Ariz., July  28, 2020  (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the launch and immediate availability of the HTG EdgeSeq Pan B-Cell Lymphoma Panel in the United States and Europe. The HTG EdgeSeq Pan B-Cell Lymphoma Panel is commercially available for purchase in kit form or as a service in HTG’s VERI/O laboratory and is available in formats specific to both the Illumina and Thermo Fisher Scientific NGS platforms.

HTG Launches New HTG EdgeSeq Pan B-Cell Lymphoma Panel

HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Will HTG Molecular Diagnostics, Inc. (HTGM) Report Negative Q2 Earnings?

Researchers at University of Pennsylvania Perelman School of Medicine and Charité University Hospitals, Berlin recognized for cutting edge work in autoimmune diseases Researchers at University of Pennsylvania Perelman School of Medicine and Charité University Hospitals, Berlin recognized for cutting edge work in autoimmune diseases

HTG Announces Recipients of Its 2020 HTG EdgeSeq Autoimmune Panel Research Grants

TUCSON, Ariz., June  25, 2020  (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has entered into a $10.0 million senior term loan agreement with Silicon Valley Bank (SVB), the bank of the world’s most innovative companies and their investors, to replace its existing senior credit facility.

HTG Molecular Diagnostics Secures Senior Term Loan from Silicon Valley Bank

TUCSON, Ariz., June  23, 2020  (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced its HTG EdgeSeq technology was highlighted in multiple posters presented by global pharma company partners at the American Association for Cancer Research (AACR) 2020 Virtual Meeting.

HTG EdgeSeq Technology Highlighted in Multiple Posters Presented by Pharma Partners at the 2020 American Association for Cancer Research Virtual Meeting

Comprehensive Panel Designed to Provide Molecular Characterization of Aggressive Lymphomas Comprehensive Panel Designed to Provide Molecular Characterization of Aggressive Lymphomas

HTG Introduces the HTG EdgeSeq Pan B-Cell Lymphoma Panel

TUCSON, Ariz., June  11, 2020  (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the signing of three new European distributor agreements to promote HTG products and services in Nordic and Eastern European Countries with BioNordika (Denmark), Explorea (Czech Republic), and ELTA 90 (Bulgaria).

HTG Adds Three New Distributors in Europe, Expanding and Strengthening Reach in the Nordics and Eastern Europe

HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q1 2020 Results - Earnings Call Transcript

HTG Molecular Diagnostics Inc (HTGM) delivered earnings and revenue surprises of 0.00% and -2.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

HTG Molecular Diagnostics Inc (HTGM) Reports Q1 Loss, Misses Revenue Estimates

Call scheduled for today, May 13, at 4:30pm ET Call scheduled for today, May 13, at 4:30pm ET

HTG Molecular Diagnostics Reports First Quarter 2020 Results

HTG Molecular Diagnostics Inc (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HTG Molecular Diagnostics Inc (HTGM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q4 2019 Results - Earnings Call Transcript

TUCSON, Ariz., Feb.  11, 2020  (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today highlighted the HTG EdgeSeq Mouse mRNA Tumor Response Panel as a way to identify endogenous targets of cardiac fibrosis as reported in the September 2019 issue of Nature.

HTG EdgeSeq Mouse mRNA Tumor Response Panel Used by Researchers Targeting Cardiac Fibrosis with Engineered T-cells

TUCSON, Ariz., Feb.  05, 2020  (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today highlighted the reproducibility of the HTG EdgeSeq miRNA Whole Transcriptome Assay (miRNA WTA), as reported in a peer-reviewed paper in the December 2019 issue of Cell Reports.

HTG EdgeSeq miRNA Whole Transcriptome Assay is Highly Reproducible in Biofluids for Potential Use as a Biomarker

TUCSON, Ariz., Jan.  28, 2020  (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has received notification of validation of European patent number EP 3356554 for its methods for subtyping diffuse large B-cell lymphoma (DLBCL), effective October 2019. HTG was previously granted a patent for this technology in the United States in 2018.

HTG Molecular Diagnostics Receives European Patent Grant Notification for Methods for Subtyping Diffuse Large B-cell Lymphoma

HTG EdgeSeq Reveal software version 2.0.0 streamlines data analysis process and enhances user experience HTG EdgeSeq Reveal software version 2.0.0 streamlines data analysis process and enhances user experience

HTG Molecular Diagnostics Expands Analytics Capabilities with Release of New Software Update

HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q3 2019 Results - Earnings Call Transcript

HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of -7.14% and -3.91%, respectively, for the quarter ended September 2019.

HTG Molecular Diagnostics, Inc. (HTGM) Reports Q3 Loss, Lags Revenue Estimates

HTG Molecular Diagnostics, Inc. (HTGM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

TUCSON, Ariz., Oct.  15, 2019  (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it will begin taking orders for its new 2,002-gene HTG EdgeSeq Autoimmune Panel, which is expected to be commercially available for purchase in kit form or as a service in HTG’s VERI/O laboratory at the end of October 2019. The HTG EdgeSeq Autoimmune Panel provides a comprehensive look into immune system dysfunction, discovery of new biomarkers and the discovery of predictive signatures of drug response in the autoimmune space. The panel is designed to address many questions around autoimmune disorders, which are chronic and often difficult to accurately diagnose. Autoimmune disorders represent a large and growing market, with annual direct U.S. healthcare costs for the treatment of autoimmune disorders being nearly double the direct U.S. healthcare costs for the treatment of cancer, and several of the largest selling pharmaceutical products are targeted towards autoimmune diseases.

HTG Announces the Launch of its New Autoimmune Profiling Assay

TUCSON, Ariz., Sept.  30, 2019  (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that John Lubniewski, President and CEO, will present a corporate overview at the Cantor 2019 Global Healthcare Conference, being held in New York City on October 2-4, 2019.

HTG Molecular to Present Corporate Overview at the Cantor 2019 Global Healthcare Conference

TUCSON, Ariz., Sept.  24, 2019  (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced the completion of its previously announced underwritten public offering of 29,298,537 shares of its common stock at a price to the public of $0.65 per share, including 3,821,548 shares sold pursuant to the exercise in full of the underwriter’s option to purchase additional shares. All of the shares in the offering were sold by HTG. The aggregate gross proceeds from the public offering are approximately $19.0 million, before deducting the underwriting discounts and commissions and offering expenses. Concurrently with the completion of the underwritten public offering, HTG completed its previously announced sale of 5,411,687 pre-funded warrants exercisable for an aggregate of 5,411,687 shares of common stock, at a purchase price of $0.64 per pre-funded warrant, to certain institutional accredited investors in a private placement. Each pre-funded warrant is immediately exercisable upon issuance, subject to beneficial ownership limitations, and has an exercise price of $0.01 per share.  The gross proceeds from the private placement are approximately $3.5 million, before deducting fees and offering expenses. 

HTG Molecular Diagnostics Announces Completion of $22.5 Million Aggregate Financing, Consisting of $19.0 Million Public Offering of Common Stock, Including the Exercise in Full of the Underwriter’s Option to Purchase Additional Shares, and $3.5 Million Co

TUCSON, Ariz., Sept.  19, 2019  (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. All of the shares are being offered by HTG. In addition, HTG expects to grant the underwriter for the offering a 30-day option to purchase additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

News for HTG Molecular Diagnostics Stock (HTGM)